Literature DB >> 23771655

Establishment of xenotransplantation model of human CN-AML with FLT3-ITD (mut) /NPM1 (-) in NOD/SCID mice.

Zhen Shang1, Jue Wang1, Di Wang1, Min Xiao1, Tong-Juan Li1, Na Wang2, Liang Huang1, Jian-Feng Zhou1.   

Abstract

Patients with FLT3-ITD (mut) /NPM1 (-) cytogenetically normal acute myeloid leukemia (CN-AML), as high-risk molecular group in CN-AML, are associated with a worse prognosis than other CN-AML patients. It is beneficial to generate xenotransplantation model of FLT3-ITD (mut) /NPM1 (-) CN-AML to better understand the pathogenesis and therapeutic strategies of such AML subtype. The purpose of present study was to establish the xenotransplantation model in NOD/SCID mice with FLT3-ITD (mut) /NPM1 (-) CN-AML primary cells. The FLT3-ITD (mut) /NPM1 (-) CN-AML primary cells from 3 of 7 cases were successfully transplanted into NOD/SCID mice, and human CD45 positive cells were detected in the peripheral blood, spleen and bone marrow of mice by using flow cytometry. Infiltration of human leukemia cells in various organs of mice was observed by using immunohistochemistry. Gene analysis confirmed sustained FLT3/ITD mutation without NPM1 mutation in mice. By performing serial transplantation, it was found that characteristics of the leukemia cells in secondary and tertiary generation models remained unchanged. Moreover, in vivo cytarabine administration could extend survival of NOD/SCID mice, which was consistent with clinical observation. In conclusion, we successfully established xenotransplantation model of human FLT3-ITD (mut) /NPM1 (-) CN-AML in NOD/SCID mice. The model was able to present primary disease and suitable to evaluate the curative effects of new drugs or therapy strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23771655     DOI: 10.1007/s11596-013-1119-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  19 in total

Review 1.  Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis.

Authors:  T Lapidot; Y Fajerman; O Kollet
Journal:  J Mol Med (Berl)       Date:  1997-09       Impact factor: 4.599

2.  Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.

Authors:  Obdulio Piloto; Mark Levis; David Huso; Yiwen Li; Hongli Li; Mei-Nai Wang; Rajiv Bassi; Paul Balderes; Dale L Ludwig; Larry Witte; Zhenping Zhu; Daniel J Hicklin; Donald Small
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

3.  Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice.

Authors:  L E Ailles; B Gerhard; H Kawagoe; D E Hogge
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

Review 4.  The roles of FLT3 in hematopoiesis and leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

5.  Human AML cells in NOD/SCID mice: engraftment potential and gene expression.

Authors:  R Lumkul; N-C Gorin; M T Malehorn; G T Hoehn; R Zheng; B Baldwin; D Small; S Gore; D Smith; P S Meltzer; C I Civin
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

6.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

7.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Authors:  D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

8.  FLT3/internal tandem duplication subclones in acute myeloid leukemia differ in their engraftment potential in NOD/SCID mice.

Authors:  Alice M S Cheung; Howard C H Chow; Yok-Lam Kwong; Raymond Liang; Anskar Y H Leung
Journal:  Leuk Res       Date:  2009-08-15       Impact factor: 3.156

9.  Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice.

Authors:  W Terpstra; A Prins; T Visser; B Wognum; G Wagemaker; B Löwenberg; J Wielenga
Journal:  Leukemia       Date:  1995-09       Impact factor: 11.528

10.  AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.

Authors:  Daniel J Pearce; David Taussig; Kazem Zibara; Lan-Lan Smith; Christopher M Ridler; Claude Preudhomme; Bryan D Young; Ama Z Rohatiner; T Andrew Lister; Dominique Bonnet
Journal:  Blood       Date:  2005-10-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.